BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 11, 2025
See today's BioWorld
Home
» ADC Therapeutics raises $200M to build momentum in antibody-drug conjugates
To read the full story,
subscribe
or
sign in
.
ADC Therapeutics raises $200M to build momentum in antibody-drug conjugates
Oct. 23, 2017
By
Cormac Sheridan
No Comments
DUBLIN – ADC Therapeutics SA (ADCT) closed $200 million in a private financing round, the fourth largest on record for a European biopharmaceutical firm.
BioWorld
